| Autor: |
Sklaroff RB, Casper ES, Magill GB, Young CW |
| Jazyk: |
angličtina |
| Zdroj: |
Cancer treatment reports [Cancer Treat Rep] 1980; Vol. 64 (12), pp. 1247-51. |
| Abstrakt: |
We conducted a phase I study of 6-diazo-5-oxo-L-norleucine given iv on a twice weekly schedule. Twenty-six evaluable patients received 31 courses of the drug. Doses ranged from 100 to 500 mg/m2. Nausea with vomiting was the dose-limiting toxic effect, transient thrombocytopenia was seen frequently, and mucositis occurred in 39% of the patients. No definite therapeutic responses were observed in 18 patients with measurable lesions. The recommended dose for phase II studies is 200-300 mg/m2 iv twice weekly. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
